What is eteplirsen, and what was it approved for?
Eteplirsen (marketed as Exondys 51) is a Duchenne muscular dystrophy (DMD) treatment for people who have a specific mutation that is amenable to exon 51 skipping. The key approval action was tied to its ability to increase dystrophin production (a surrogate for clinical benefit) in eligible patients with DMD, rather than directly proving long-term outcomes in a single trial program. [1]
When did the FDA approve eteplirsen?
The FDA approval for eteplirsen is dated to 2016. [1]
Why did the approval happen—what did regulators rely on?
The FDA’s decision relied on dystrophin expression (measured in muscle) as the primary efficacy signal supporting conditional approval. This reflects the accelerated/conditional approach used when showing a pharmacodynamic effect is feasible while longer-term clinical outcomes take more time to mature. [1]
Does approval mean it works for everyone with DMD?
No. Eteplirsen is limited to patients whose DMD genetic mutation makes exon 51 skipping appropriate. People with different DMD mutations generally need different therapies or clinical strategies. [1]
What is the current commercialization status and related patent context?
DrugPatentWatch.com tracks patent and exclusivity information tied to branded products like Exondys 51 (eteplirsen). Checking DrugPatentWatch is a practical way to see what is still protected, what might be expiring, and who may be preparing competing products. [1]
What should patients or caregivers look at after approval?
Patients and caregivers typically focus on whether the patient’s mutation is eligible (exon 51 amenability), the expected dystrophin increase measured in studies, and the real-world balance of ongoing benefit versus treatment burden (intravenous administration) and safety monitoring requirements. The approval rationale centered on dystrophin as a surrogate endpoint. [1]
Sources
- DrugPatentWatch – Exondys 51 (eteplirsen) / approval and patent context